Annexon, Inc. Appoints Dr. Mark Blumenkranz to Board; Director Resigns

What Happened
Annexon, Inc. (ANNX) filed an 8-K on August 10, 2026 announcing that long-time director Muneer Satter resigned from the Board, the Audit Committee and as chair of the Nominating and Corporate Governance Committee effective immediately prior to the appointment of Mark S. Blumenkranz, M.D., M.S.S. Dr. Blumenkranz was appointed to the Board the same day as a Class II director, with a term expiring at the 2028 annual meeting. The filing states Mr. Satter’s resignation was not due to any disagreement with the company.

Key Details

• Appointment effective date: August 10, 2026; term expires at the 2028 annual meeting.
• Committee assignments: Dr. Blumenkranz joins the Audit Committee and the Science & Technology Committee.
• Director compensation: $40,000 annual retainer; automatic annual stock option grant of 65,000 shares (vesting at earlier of one year or next annual meeting). In lieu of the automatic initial grant, Dr. Blumenkranz received a one-time option to purchase 175,000 shares under the 2020 Incentive Award Plan.
• Governance items: Dr. Blumenkranz executed the company’s standard indemnification and advancement agreement; no related-party transactions or family relationships disclosed.

Why It Matters
Board changes affect company governance and oversight. The addition of Dr. Blumenkranz—identified in the company’s press release as a retinal surgeon and biotech entrepreneur—adds scientific and industry expertise to Annexon’s board and to its Audit and Science & Technology Committees. The stock option grant and annual retainer are standard non-employee director compensation and represent potential future dilution if options are exercised. The filing does not indicate any operational disagreement or other material concerns tied to the resignation.